Evidence map›Paper›PMID 31332819›Full record

Observational studyPharmacotherapy2019

Association between Use of Methadone, Other Central Nervous System Depressants, and QTc Interval-Prolonging Medications and Risk of Mortality in a Large Cohort of Women Living with or at Risk for Human Immunodeficiency Virus Infection.

Bani Tamraz, Lori Reisner, Audrey L French, Samuel T King, Margaret A Fischl, Igho Ofotokun, Angela Kashuba, Joel Milam, Kerry Murphy, Michael Augenbraun and 7 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Pharmacotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Bani TamrazSchool of Pharmacy, University of California, San Francisco, San Francisco, California.ORCID 0000-0002-7341-455X
Lori ReisnerDepartment of Neurological Surgery, University of California, San Francisco, San Francisco, California.
Audrey L FrenchInfectious Diseases, CORE Center/Stroger Hospital of Cook County, Chicago, Illinois.
Samuel T KingDepartment of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, Mississippi.
Margaret A FischlDivision of Infectious Diseases, Miller School of Medicine, University of Miami, Miami, Florida.
Igho OfotokunDivision of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia.
Angela KashubaSchool of Pharmacy, UNC Eshelman, University of North Carolina (UNC) Center for AIDS Research, Chapel Hill, North Carolina.
Joel MilamKeck School of Medicine, University of Southern California, Los Angeles, California.
Kerry MurphyDepartment of Medicine, Albert Einstein College of Medicine, Bronx, New York.
Michael AugenbraunInfectious Diseases, State University of New York Downstate Medical Center, Brooklyn, New York.
Chenglong LiuDepartment of Medicine, Georgetown University Medical Center, Washington, District of Columbia.
Patrick R FinleySchool of Pharmacy, University of California, San Francisco, San Francisco, California.
Bradley AouizeratSchool of Dentistry and Bluestone Center for Clinical Research, New York University, New York, New York.
Jennifer CocohobaSchool of Pharmacy, University of California, San Francisco, San Francisco, California.
Stephen GangeJohn Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Peter BacchettiDepartment of Epidemiology and Biostatistics, School of Medicine, University of California, San Francisco, San Francisco, California.
Ruth M GreenblattSchool of Pharmacy, University of California, San Francisco, San Francisco, California.

Funding

Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Women's Interagency HIV Study (WIHS-V)U01AI035004 · NIAID · MONTEFIORE MEDICAL CENTER (BRONX, NY) · PI ANASTOS, KATHRYN M., SHARMA, ANJALI · 1993 to 2018
$65.7M
WOMEN'S INTERAGENCY HIV STUDY ORGANIZATION, MANAGEMENT AND COMMUNICATIONSU01AI034989 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI AOUIZERAT, BRADLEY E, GREENBLATT, RUTH MARTHA · 1993 to 2018
$65.6M
Women's Interagency HIV Study (WIHS) IIIU01AI031834 · NIAID · SUNY DOWNSTATE MEDICAL CENTER · PI GUSTAFSON, DEBORAH R., MINKOFF, HOWARD · 1998 to 2018
$53.5M
WOMEN'S INTERAGENCY HIV STUDY (WIHS) ORGANIZATION AND MANAGEMENTU01AI034994 · NIAID · GEORGETOWN UNIVERSITY · PI KASSAYE, SEBLE G · 1993 to 2018
$52.0M
Women's Interagency HIV Study (WIHS) IV, Chicago ConsortiumU01AI034993 · NIAID · HEKTOEN INSTITUTE FOR MEDICAL RESEARCH · PI COHEN, MARDGE H, FRENCH, AUDREY · 1994 to 2018
$51.0M
WOMENS INTERAGENCY HIV STUDY (WIHS)U01HD032632 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MILAM, JOEL E · 1994 to 2012
$42.0M
WIHS DATA MANAGEMENT AND ANALYSIS CENTER(WDMAC)U01AI042590 · NIAID · JOHNS HOPKINS UNIVERSITY · PI GANGE, STEPHEN J, GOLUB, ELIZABETH T · 1998 to 2018
$38.4M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
MACS/WIHS Combined Cohort Study Clinical Research SiteU01HL146241 · NHLBI · EMORY UNIVERSITY · PI Cecile Delille Lahiri, Anandi Nayan Sheth · 2019 to 2026
$24.2M
NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR000454NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146242NIAID NIH HHS R38 AI140299NIAID NIH HHS U01 AI031834NIAID NIH HHS U01-AI-031834NIAID NIH HHS U01 AI034989NIAID NIH HHS U01-AI-034989NIAID NIH HHS U01 AI034993NIAID NIH HHS U01-AI-034993NIAID NIH HHS U01 AI034994NIAID NIH HHS U01-AI-034994NIAID NIH HHS U01 AI035004NIAID NIH HHS U01-AI-035004NIAID NIH HHS U01 AI042590NIAID NIH HHS U01-AI-042590NIAID NIH HHS U01 AI103390NIAID NIH HHS U01-AI-103390NIAID NIH HHS U01 AI103397NIAID NIH HHS U01-AI-103397NIAID NIH HHS U01 AI103401NIAID NIH HHS U01-AI-103401NIAID NIH HHS U01 AI103408NIAID NIH HHS U01-AI-103408NICHD NIH HHS U01 HD032632NICHD NIH HHS U01-HD-032632NIH HHS P30 A1027763NIH HHS UL1-TR000004NIH HHS UL1-TR000454
6 · The paper itself

Abstract

STUDY

objectiveTo evaluate the association between use of methadone, other central nervous system (CNS) depressants, and QTc interval-prolonging medications and risk of mortality among human immunodeficiency virus (HIV)-infected and at-risk HIV-uninfected women.

designMulticenter, prospective, observational cohort study (Women's Interagency HIV Study [WIHS]).

participantsA total of 4150 women enrolled in the WIHS study between 1994 and 2014 who were infected (3119 women) or not infected (1031 women) with HIV. MEASUREMENTS AND MAIN

resultsData on medication utilization were collected from all study participants via interviewer-administered surveys at 6-month intervals (1994-2014). Mortality was confirmed by National Death Index data. With age defining the time scale for the analysis, Cox proportional hazards models were used to estimate hazard ratios (HRs) for all-cause mortality in HIV-infected and -uninfected women and non-acquired immunodeficiency syndrome (AIDS) deaths in HIV-infected women. A total of 1046 deaths were identified, of which 429 were considered non-AIDS deaths. Use of benzodiazepines, CNS depressants (excluding methadone), and number of medications with conditional QTc interval-prolonging effects were each associated with all-cause mortality in multivariate models of HIV-infected women: hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.01-1.60, p=0.037; HR 1.61, 95% CI 1.35-1.92, p<0.0001; and HR 1.15 per drug, 95% CI 1.00-1.33, p=0.047, respectively. Other explanatory variables for all-cause mortality in this model included HIV viral load, CD4

conclusionIn this cohort of HIV-infected and at-risk HIV-uninfected women, use of benzodiazepines, CNS depressants, and conditional QTc interval-prolonging medications were associated with a higher risk of mortality independent of methadone and other well-recognized mortality risk factors. Care must be taken to assess risk when prescribing these medications in this underserved and at-risk patient population.

Indexed as

Acquired Immunodeficiency SyndromeAdolescentAdultAgedBenzodiazepinesCause of DeathCD4 Lymphocyte CountCentral Nervous System DepressantsDepressionElectrocardiographyFemaleHemoglobinsHIV InfectionsHumansKidney Function TestsLong QT SyndromeBenzodiazepinesCentral Nervous System DepressantsHemoglobinsMethadoneSerum Albuminarrhythmias cardiacbenzodiazepinescentral nervous system depressantsHIV infectionsmethadonemortality

Identifiers

PMID31332819
PMCPMC7000174

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.